Potential of using boric acid as a boron drug for boron neutron capture therapy for osteosarcoma

C F Hsu; S Y Lin; J J Peir; J W Liao; Y C Lin; F I Chou

doi:10.1016/j.apradiso.2011.03.003

Potential of using boric acid as a boron drug for boron neutron capture therapy for osteosarcoma

Appl Radiat Isot. 2011 Dec;69(12):1782-5. doi: 10.1016/j.apradiso.2011.03.003. Epub 2011 Mar 21.

Authors

C F Hsu¹, S Y Lin, J J Peir, J W Liao, Y C Lin, F I Chou

Affiliation

¹ Institute of Nuclear Engineering and Science, National Tsing Hua University, Taiwan, ROC.

PMID: 21420871
DOI: 10.1016/j.apradiso.2011.03.003

Abstract

Osteosarcoma is a malignant tumor commonly found in human and animals. The ability of boric acid (BA) to accumulate in osteosarcoma due to the mechanism of the bone formation of cancer cells would make boron neutron capture therapy (BNCT) an alternative therapy for osteosarcoma. This study evaluated the feasibility of using BA as the boron drug for BNCT of bone cancer. The cytotoxicity of BA to L929 cells exceeded that of UMR-106 cells. With 25 μg (10)B/mL medium of BA treatment, the boron concentration in UMR-106 cells was higher than that in L929 cells. The biodistribution and pharmacokinetics of BA in Sprague-Dawley (SD) rats were studied by administrating 25 mg (10)B/kg body weight to SD rats. Blood boron level decreased rapidly within one hour after BA injection. Boron concentration in the long bone was 4-6 time higher than that of blood. Results of this study suggest that BA may be a potential drug for BNCT for osteosarcoma.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Animals
Bone Neoplasms / radiotherapy*
Boric Acids / pharmacokinetics
Boric Acids / therapeutic use*
Boron Neutron Capture Therapy*
Cell Line, Tumor
Male
Osteosarcoma / radiotherapy*
Rats
Rats, Sprague-Dawley
Tissue Distribution

Substances

Boric Acids
boric acid